SWOG clinical trial number
SWOG-9248

A Phase II Trial of Paclitaxel (Taxol ®) in Patients with Metastatic Refractory Carcinoma of the Breast

Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Phase II Trial of Paclitaxel (Taxol ®) in Patients with Metastatic Refractory Carcinoma of the Breast
Activated
06/01/1993
Closed
02/01/1994

Research committees

Breast Cancer

Publication Information Expand/Collapse

2014

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

2000

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

1998

Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study.

CE Geyer Jr;SJ Green;CM Moinpour;J O'Sullivan;DK Goodwin;VA Canfield;FJ Meyers;CK Osborne;S Martino Breast Cancer Research and Treatment 51:169-181

1996

A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: A Southwest Oncology Group (SWOG) study.

CE Geyer Jr;SJ Green;C Moinpour;J O'Sullivan;D Goodwin;V Canfield;V Hamaski;S Martino American Society of Clinical Oncology 15:107(#92)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
31%
Open
Phase